ORAL TREATMENT WITH NICORANDIL AT DISCHARGE IS ASSOCIATED WITH REDUCED MORTALITY AFTER ACUTE MYOCARDIAL INFARCTION
Background. Previous studies showed that nicorandil can reduce coronary events in patients with coronary artery disease. However, it is unclear whether oral nicorandil treatment may reduce mortality following acute myocardial infarction (AMI). Methods and Results. We examined the impact of oral nico...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2012-10-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/1288 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850029015025319936 |
|---|---|
| author | Y. Sakata D. Nakatani M. Shimizu Sh. Suna M. Usami S. Matsumoto M. Hara S. Sumitsuji Sh. Kawano K. Iwakura T. Hamasaki H. Sato Sh. Nanto M. Hori I. Komuro |
| author_facet | Y. Sakata D. Nakatani M. Shimizu Sh. Suna M. Usami S. Matsumoto M. Hara S. Sumitsuji Sh. Kawano K. Iwakura T. Hamasaki H. Sato Sh. Nanto M. Hori I. Komuro |
| author_sort | Y. Sakata |
| collection | DOAJ |
| description | Background. Previous studies showed that nicorandil can reduce coronary events in patients with coronary artery disease. However, it is unclear whether oral nicorandil treatment may reduce mortality following acute myocardial infarction (AMI). Methods and Results. We examined the impact of oral nicorandil treatment on cardiovascular events in 1846 AMI patients who were hospitalized within 24 h after AMI onset, treated with emergency percutaneous coronary intervention (PCI), and discharged alive. Patients were divided into those with (Group N, n = 535) and without (Group C, n = 1311) oral nicorandil treatment at discharge. No significant differences in age, gender, body mass index, prevalence of coronary risk factors, or history of myocardial infarction existed between the two groups; however, higher incidences of multi-vessel disease, and a lower rate of successful PCI were observed in Group N. During the median follow-up of 709 (340–1088) days, allcause mortality rate was 43% lower in Group N compared with Group C (2.4% vs. 4.2%, stratified log-rank test: p = 0.0358). Multivariate Cox regression analysis revealed that nicorandil treatment was associated with all-cause death after discharge (Hazard ratio 0.495, 95% CI: 0.254–0.966, p = 0.0393), but not for other cardiovascular events such as re-infarction, admission for heart failure, stroke and arrhythmia. Conclusions. The results suggest that oral administration of nicorandil is associated with reduced incidence of death in the setting of secondary prevention after AMI. |
| format | Article |
| id | doaj-art-2eda4b76b6424e5989b4ce2f51c0cbba |
| institution | DOAJ |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| publishDate | 2012-10-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj-art-2eda4b76b6424e5989b4ce2f51c0cbba2025-08-20T02:59:39Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202012-10-010590971083ORAL TREATMENT WITH NICORANDIL AT DISCHARGE IS ASSOCIATED WITH REDUCED MORTALITY AFTER ACUTE MYOCARDIAL INFARCTIONY. Sakata0D. Nakatani1M. Shimizu2Sh. Suna3M. Usami4S. Matsumoto5M. Hara6S. Sumitsuji7Sh. Kawano8K. Iwakura9T. Hamasaki10H. Sato11Sh. Nanto12M. Hori13I. Komuro14Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, JapanDepartment of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, JapanDepartment of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, JapanDepartment of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, JapanDepartment of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, JapanDepartment of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, JapanDepartment of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, JapanDepartment of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Osaka Department of Advanced Cardiovascular Therapeutics, Osaka University Graduate School of Medicine, Suita, OsakaCardiovascular Division, Kawachi General Hospital, Higashi-osaka, OsakaDivision of Cardiology, Sakurabashi Watanabe Hospital, Osaka, OsakaDepartment of Biomedical Statistics, Osaka University Graduate School of Medicine, Suita, OsakaSchool of Human Welfare Studies Health Care Center and Clinic, Kwansei Gakuin University, Nishinomiya, OsakaDepartment of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Osaka Department of Advanced Cardiovascular Therapeutics, Osaka University Graduate School of Medicine, Suita, OsakaOsaka Medical Center for Cancer and Cardiovascular Disease, Osaka, OsakaOsaka Medical Center for Cancer and Cardiovascular Disease, Osaka, OsakaBackground. Previous studies showed that nicorandil can reduce coronary events in patients with coronary artery disease. However, it is unclear whether oral nicorandil treatment may reduce mortality following acute myocardial infarction (AMI). Methods and Results. We examined the impact of oral nicorandil treatment on cardiovascular events in 1846 AMI patients who were hospitalized within 24 h after AMI onset, treated with emergency percutaneous coronary intervention (PCI), and discharged alive. Patients were divided into those with (Group N, n = 535) and without (Group C, n = 1311) oral nicorandil treatment at discharge. No significant differences in age, gender, body mass index, prevalence of coronary risk factors, or history of myocardial infarction existed between the two groups; however, higher incidences of multi-vessel disease, and a lower rate of successful PCI were observed in Group N. During the median follow-up of 709 (340–1088) days, allcause mortality rate was 43% lower in Group N compared with Group C (2.4% vs. 4.2%, stratified log-rank test: p = 0.0358). Multivariate Cox regression analysis revealed that nicorandil treatment was associated with all-cause death after discharge (Hazard ratio 0.495, 95% CI: 0.254–0.966, p = 0.0393), but not for other cardiovascular events such as re-infarction, admission for heart failure, stroke and arrhythmia. Conclusions. The results suggest that oral administration of nicorandil is associated with reduced incidence of death in the setting of secondary prevention after AMI.https://russjcardiol.elpub.ru/jour/article/view/1288nicorandilacute myocardialinfarctionmortalitysecondary prevention |
| spellingShingle | Y. Sakata D. Nakatani M. Shimizu Sh. Suna M. Usami S. Matsumoto M. Hara S. Sumitsuji Sh. Kawano K. Iwakura T. Hamasaki H. Sato Sh. Nanto M. Hori I. Komuro ORAL TREATMENT WITH NICORANDIL AT DISCHARGE IS ASSOCIATED WITH REDUCED MORTALITY AFTER ACUTE MYOCARDIAL INFARCTION Российский кардиологический журнал nicorandil acute myocardial infarction mortality secondary prevention |
| title | ORAL TREATMENT WITH NICORANDIL AT DISCHARGE IS ASSOCIATED WITH REDUCED MORTALITY AFTER ACUTE MYOCARDIAL INFARCTION |
| title_full | ORAL TREATMENT WITH NICORANDIL AT DISCHARGE IS ASSOCIATED WITH REDUCED MORTALITY AFTER ACUTE MYOCARDIAL INFARCTION |
| title_fullStr | ORAL TREATMENT WITH NICORANDIL AT DISCHARGE IS ASSOCIATED WITH REDUCED MORTALITY AFTER ACUTE MYOCARDIAL INFARCTION |
| title_full_unstemmed | ORAL TREATMENT WITH NICORANDIL AT DISCHARGE IS ASSOCIATED WITH REDUCED MORTALITY AFTER ACUTE MYOCARDIAL INFARCTION |
| title_short | ORAL TREATMENT WITH NICORANDIL AT DISCHARGE IS ASSOCIATED WITH REDUCED MORTALITY AFTER ACUTE MYOCARDIAL INFARCTION |
| title_sort | oral treatment with nicorandil at discharge is associated with reduced mortality after acute myocardial infarction |
| topic | nicorandil acute myocardial infarction mortality secondary prevention |
| url | https://russjcardiol.elpub.ru/jour/article/view/1288 |
| work_keys_str_mv | AT ysakata oraltreatmentwithnicorandilatdischargeisassociatedwithreducedmortalityafteracutemyocardialinfarction AT dnakatani oraltreatmentwithnicorandilatdischargeisassociatedwithreducedmortalityafteracutemyocardialinfarction AT mshimizu oraltreatmentwithnicorandilatdischargeisassociatedwithreducedmortalityafteracutemyocardialinfarction AT shsuna oraltreatmentwithnicorandilatdischargeisassociatedwithreducedmortalityafteracutemyocardialinfarction AT musami oraltreatmentwithnicorandilatdischargeisassociatedwithreducedmortalityafteracutemyocardialinfarction AT smatsumoto oraltreatmentwithnicorandilatdischargeisassociatedwithreducedmortalityafteracutemyocardialinfarction AT mhara oraltreatmentwithnicorandilatdischargeisassociatedwithreducedmortalityafteracutemyocardialinfarction AT ssumitsuji oraltreatmentwithnicorandilatdischargeisassociatedwithreducedmortalityafteracutemyocardialinfarction AT shkawano oraltreatmentwithnicorandilatdischargeisassociatedwithreducedmortalityafteracutemyocardialinfarction AT kiwakura oraltreatmentwithnicorandilatdischargeisassociatedwithreducedmortalityafteracutemyocardialinfarction AT thamasaki oraltreatmentwithnicorandilatdischargeisassociatedwithreducedmortalityafteracutemyocardialinfarction AT hsato oraltreatmentwithnicorandilatdischargeisassociatedwithreducedmortalityafteracutemyocardialinfarction AT shnanto oraltreatmentwithnicorandilatdischargeisassociatedwithreducedmortalityafteracutemyocardialinfarction AT mhori oraltreatmentwithnicorandilatdischargeisassociatedwithreducedmortalityafteracutemyocardialinfarction AT ikomuro oraltreatmentwithnicorandilatdischargeisassociatedwithreducedmortalityafteracutemyocardialinfarction |